Teva Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee recommended approval of reslizumab, a humanized anti-interleukin-5 (IL-5) IgG4K monoclonal antibody (mAb), in adult patients aged 18 years and older. Reslizumab is a targeted biologic therapy for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based treatment regimen.
“Patient stratification based on eosinophil levels has been an important advancement in the treatment of asthma,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “We are very encouraged by the outcome of today’s FDA Advisory Committee meeting, which brings us one step closer to potentially providing a new, targeted treatment option for a specific group of patients with inadequately controlled asthma and evidence of ongoing eosinophilic inflammation. This group of patients often experiences persistent symptoms despite standard-of-care treatment, demonstrating a need for more targeted treatment options based on patient phenotype.”
The Advisory Committee's recommendation will be considered by the FDA in its review of the Biologics License Application (BLA) for reslizumab. The FDA is not bound by the Committee's recommendation, but takes its advice into consideration when reviewing investigational medicines. The reslizumab BLA was accepted for standard review by the FDA and Regulatory Action is expected in March 2016. Additional regulatory filings for reslizumab have been completed in the EU and Canada.
